Development
Ocular Therapeutix, Inc.
OCUL
$8.19
-$0.14-1.68%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -88.01% | 97.87% | -10.21% | -141.73% | -303.69% |
| Total Depreciation and Amortization | 95.11% | 74.85% | 18.12% | -13.29% | -13.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,321.49% | -317.19% | 67.16% | 891.93% | 102.10% |
| Change in Net Operating Assets | -206.93% | 59.01% | -199.03% | 50.53% | -107.28% |
| Cash from Operations | -32.41% | 41.29% | -84.58% | -7.38% | -11.91% |
| Capital Expenditure | 78.65% | 67.38% | -302.02% | -1,124.28% | -240.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 78.65% | 67.38% | -302.02% | -1,124.28% | -240.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 23,517.90% | 105.88% | 1,856.39% | -39.53% | -31.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 23,517.90% | 13,786.36% | 1,856.39% | -39.53% | -31.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 557.14% | 423.38% | -14.18% | -24.15% | -23.37% |